Literature DB >> 21562724

Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.

Johannes Levin, Joachim Neudert, Ludwig Zwermann, Michael Näbauer, Kai Bötzel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21562724     DOI： 10.1007/s00415-011-6077-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

1.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

Authors:  Guy Van Camp; Anja Flamez; Bernard Cosyns; Caroline Weytjens; Luc Muyldermans; Michel Van Zandijcke; Johan De Sutter; Patrick Santens; Pierre Decoodt; Christian Moerman; Danny Schoors
Journal:  Lancet       Date:  2004-04-10       Impact factor: 79.321

2.  Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.

Authors:  Reinhard Horowski; Sven Jähnichen; Heinz H Pertz
Journal:  Mov Disord       Date:  2004-12       Impact factor: 10.338

3.  Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.

Authors:  Mitsutoshi Yamamoto; Tadahisa Uesugi; Takeo Nakayama
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

Review 4.  Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.

Authors:  M Horstink; E Tolosa; U Bonuccelli; G Deuschl; A Friedman; P Kanovsky; J P Larsen; A Lees; W Oertel; W Poewe; O Rascol; C Sampaio
Journal:  Eur J Neurol       Date:  2006-11       Impact factor: 6.089

Review 5.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Authors:  Angelo Antonini; Werner Poewe
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

6.  Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.

Authors:  Evzen Růzicka; Hana Línková; Martin Penicka; Olga Ulmanová; Lucie Nováková; Jan Roth
Journal:  J Neurol       Date:  2007-08-24       Impact factor: 6.682
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.